Articles On Botanix Pharmaceuticals (ASX:BOT)

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by selling stocks you do not actually own in the hope of bu...

Emerging or early-stage companies offer new investment opportunities to investors, and higher returns are expected from start-ups due to their potential for growth. Investing in early-stage companies is risky; however, it offers the potenti...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by selling stocks you do not actually own in the hope of bu...

In the year 2019, marijuana stocks were among the hot picks for investors, despite the general market impulsiveness, strong competition and economic pressures. Recently, a green signal has been given to a bill legalising marijuana on the st...

Health care in Australia is the most diversified and dynamic sector and has the potential to generate significant revenues for the Australian economy. The health care sector comprises of companies engaged in drug development and R&D act...

In this article we are discussing five ASX-listed health care stocks, Althea Group Holdings Limited (ASX: AGH), Botanix Pharmaceuticals Limited (ASX:BOT), SDI Limited (ASX: SDI), Mach7 Technologies Limited (ASX: M7T), OncoSil Medical Limite...

Cannabis has been progressively decriminalised around the world since the early 2000s, starting with Canada granting legal access for medical purposes in 2001 and several other countries following suit. It has taken Australia 15 years to ca...

Cannabis Shares Valuing a cannabis company is becoming an increasingly difficult task. Lately, the cannabis shares have been taking a beat in the domestic markets, falling from their respective all-time highs. The table below provides you w...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

Each Monday, Stockhead recaps which stocks are most heavily in demand by investors — running hot. The analysis is based on the Relative Strength Index (RSI), a technical gauge which measures how trading momentum is affecting the price actio...

Here’s our fortnightly wrap of the major small cap health stock winners and losers.  One small cap ASX healthcare company has stormed home to top the tables at the end of October. Novita Healthcare (ASX:NHL) shares have exploded 500 per cen...

It’s been a year of highs and lows for cannabis shares. Marijuana shares were favourites of investors earlier this year but have since suffered setbacks: the vaping crisis in the United States (US) as well as issues on the home front have...

Cannabis is a fast-growing industry with a dynamic and rapidly changing prospects, the medicinal cannabis stocks are progressing on the right track to capture investors’ attention and maximum addressable market. Players dealing in medicinal...

Health care system of Australia is considered as one of the best, globally, as it delivers safe and affordable health care solutions and services to the citizens. Health care sector in Australia comprises of medical service, medical insuran...

Health care sector is one of the popular sectors among investors, as it is one of the high yielding sectors. However, at times, investors also lose their money, when health care stocks engaged in research & development activities fail t...

Pn this day in 2001, Apple announced the release of the first iPod player. The iPod became the world's biggest-selling portable media player; six years after its initial launch, Apple announced that 100 million devices had been sold. The co...

Amidst the global market fickleness, competition and economic pressure, cannabis stocks stand out as the hot pick stocks for investors.  The Cannabis stocks are gaining traction with the sector growing at a fast pace with new listings and i...

Listed cannabis stocks worldwide have pulled back from their highs lately, tainted by the vaping crisis in the US. Canopy Growth has seen its share price drift down to just above US$20 from highs of over US$50 in April. Rival Aurora Cannab...

In afternoon trade the S&P/ASX 200 index is on course to give back yesterday’s gains. At the time of writing the benchmark index is down 0.25% to 6,655.5 points. Four shares that have fallen more than most today are listed below. Here’...

Botanix Pharmaceuticals’ (ASX:BOT) shares have halved after its anti-acne drug failed its clinical trial. If you read most of the company’s announcement and you’d would have thought the 368 patient trial was a success. Its drug, BTX 1303, w...

The Elixinol Global Ltd (ASX: EXL) share price has come under significant selling pressure today after returning from a trading halt. The diversified cannabis company’s shares crashed 10% lower to $1.92 this morning. Why did the Elixinol G...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

It looks set to be a disappointing day of trade for the Botanix Pharmaceuticals Ltd (ASX: BOT) share price on Wednesday. The cannabis-focused medical dermatology company’s shares look set to be sold off after a disappointing study result....

Drug development company Noxopharm (ASX: NOX) is growing more optimistic about the use of its Veyonda treatment on patients with late-stage prostate cancer. NOX provided an interim update on its DARRT-1 clinical trial, where patients are gi...

In the few short years since cannabis companies first floated on stock exchanges around the world, they have developed a reputation for being volatile and high risk. At the start, stocks exploded in value, peaking around the start of 2018....

Clinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has been awarded a new Innovation Connections Grant by federal agency AusIndustry.

Biotech company Immutep (ASX:IMM) just got some positive results in a Phase I clinical trial for its cancer-fighting treatment. Phase I trials are used to test safety of a given drug, before Phase II trials which measure effectiveness. Immu...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by “selling” stocks you do not actually own in the hope of...

Clinical stage Australian-based cannabinoid company Botanix Pharmaceuticals (ASX:BOT) says it has a ne product opportunity for the treatment of papulopustular rosacea.

Introduction Investors seek high return on stocks and continue to invest in the stock market. Investors with higher risk-taking abilities are rewarded higher. However, in most of the cases, investors tend to lose their capital because of la...

‘Pot stocks’ were making headlines in 2018. California, one of the world’s biggest economies and the most populous state in the US, finally enacted legislation to legalise the recreational use of cannabis. It joined a growing list of US st...

Digital healthcare service has evolved as one of the fastest-growing industries in the modern era. Introduction of technology in medical science has emerged as one of the biggest blessings for human. Digitally connected network systems have...

The federal government has taken steps to cut red tape and speed up the granting of licences for Australia’s cannabis players. Health Minister Greg Hunt said the federal government would boost the nation’s medicinal cannabis industry by pri...

Opthea (ASX: OPT) shares have more than doubled this morning after announcing its Phase IIb clinical trial was a success. The 366-patient study tested its OPT-302 drug, which battles wet (neovascular) age-related macular degeneration (AMD)...

On the cusp of what Botanix (ASX: BOT) is calling "one of the most significant chapters" in the development of its cannabis portfolio, the company has completed a $40 million capital raising. The oversubscribed share placement was led by...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is sagging today after the company made two announcements to the ASX during a two-day trading halt. On Monday trading, BOT shares closed at 26 cents per share, but re-opened this morni...

Botanix Pharmaceuticals Limited (ASX: BOT) is an Australian-headquartered company, engaged in the development of next-gen therapeutics that are safe and effective for the treatment of serious skin diseases. It is a clinical stage cannabinoi...

Skin treatments company Botanix Pharmaceuticals is in front of investors seeking a $40 million equity injection on Tuesday. 

A new chain of medical cannabis clinics are set to roll out across Australia as part of a collaboration between Australian biopharma Zelda Therapeutics (ASX:ZLD) and Emerald Clinics. Zelda is developing a new cannabis-based treatment to red...

The biotechnology sector is one of those sectors that presents an incredible opportunity for huge returns to investors. This is because the business of curing diseases can be lucrative, and any company with a small market capitalisation can...

Clinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has announced new data from studies recently conducted involving its cannabidiol antimicrobial platform and a new development program ‘AB 2367’.

The below-mentioned healthcare stocks have provided significant returns in the last six months and have come up with major updates today (i.e. 15th July 2019).  Let’s take a look at these updates. Rhinomed Limited (ASX: RNO) A Melbourne-ba...

Although it has fought back from its lows, the S&P/ASX 200 index is still on course to start the week on a disappointing note. At the time of writing the benchmark index is down 0.35% to 6,672.5 points. Four shares that have not let th...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price has continued its impressive run and is up over 14% to 24 cents in morning trade. This means the clinical stage cannabinoid company’s shares have gained almost 250% since the start of...

Adherium (ASX: ADR) shares have risen 19 per cent this morning following news the asthma monitoring firm had received clearance to sell its devices in the US. The Food and Drug Administration (FDA) granted 510(k) clearance for its Hailie se...

As the cannabis sector gains momentum in Australia and given that medicinal cannabis was legalised in February 2016, at a federal level, various companies are rapidly advancing their clinical trials for relevant products to capitalise on th...

The Australian share market may have dropped off a touch this week, but that hasn’t stopped a number of shares from continuing their charge. Three shares that reached 52-week highs or better this week are listed below. Here’s why they have...

Do you know that market enthusiasts believe that legalising cannabis would generate approximately $8.5 billion in the country’s federal and state tax? Ponder over the massive revenue that this sector would add to the necessities related to...

I think it is fair to say that 2019 has been a very positive year for Australian investors. Since the turn of the year the All Ordinaries index has pushed a sizeable 20% higher. Whilst this means that the majority of local shares are recor...